Asia’s Largest Pharmaceutical/Biotechnology Event held in Japan

22nd INTERPHEX JAPAN

8 th INT’L BIO FORUM & BIO EXPO JAPAN

PHARMA i JAPAN 2009

Asia’s Largest Pharmaceutical/Biotechnology Event held in Japan

On July 1 (Wed) – 3 (Fri), Asia’s largest show in the Pharmaceutical/Biotechnology industry, 22 nd INTERPHEX JAPAN, 8 th INT’L BIO FORUM & BIO EXPO JAPAN, and PHARMA i JAPAN 2009 wasgrandly held with the record number of 1,614 exhibitors and 55,964 visitors. At the show venue many scenes were witnessed where exhibitors and visitors did concrete business meetings during the show. The three exhibitions are a must visit for professionals within the pharmaceutical, biotechnology, and cosmetic manufacturers industry, as this is the one and only event throughout Japan where you can see the upstream to downstream of this industry.

In addition to the exhibition venue, conference room was filled with professionals keen to know the latest technologies and trends of the life science in Japan and Asia .


EXHIBITION OUTLINE
Exhibition ： INT’L BIO FORUM & BIO EXPO JAPAN
INTERPHEX JAPAN
PHARMA i JAPAN

Dates ： July 1 [Wed] - 3 [Fri], 2009
Open Hours ： 10:00-18:00 (10:00-17:00 on July 3)
Venue ： Tokyo Big Sight , Japan
Organised by ： Reed Exhibitions Japan Ltd.

8 th INT’L BIO FORUM & BIO EXPO JAPAN

What is INT’L BIO FORUM & BIO EXPO JAPAN ? It is Asia’s largest BIO event where bio-related people, products, technologies and information all gathers across Asia .

Special Zones and Fairs :

Drug Discovery Area
CRO and Contract Research Services Zone
Proteome Area
DNA/RNA Area
Biochip Zone NT’L BIO FORUM & BIO EXPO JAPAN
Biohazard Zone
Bioinformatics/Data-management Zone
Cell Area
Fine Processing/Prototype Manufacutring Zone
Bio-imaging Zone

Cell Area
This area is one of the attention getter areas, as ES/iPS cell is making its way to practical use.

Consisting of companies dealing with products and technologies such as cell analysis, tissue-engineering technologies, and cell research, various new companies exhibited for the first time. Hitachi Plant Technologies Ltd. brought in new products including cell processing management system, which contributes to decrease cross contamination in clean rooms utilized electronic signature.

Genetic Testing & Diagnostics 2009

The development of genetic testing technology is striking, as the application of this business is rapidly growing with its realization of low-cost and the improvement of inspection accuracy efficiency. From disorder such as cancer, to beauty business such as diet, the expansion of the business is anticipated for the genetic testing and diagnostics technology. Toray Industries brought in “3-D Gene”, an ultra-high sensitive DNA chip, and Toshiba brought in “automated DNA detection system genelyzer”, an all-in-one system fro hybridization to analysis.

22 nd INTERPHEX JAPAN

What is INTERPHEX JAPAN ? It is an international exhibition and conference for pharmaceutical, cosmetic and detergent R&D and manufacturing technology.

Special Zones and Fairs :

Pharma Sourcing
Pharma IT
Pharma Pack
LOGISTICS
Sterlizing Equipment & Clean Room Zone
Energy-saving Solution/Facility Fair
Factory Facility & Equipment Zone
Process Inspection/Testing Equipment Zone

22 nd INTERPHEX JAPAN

Pharma & Cosmetic Packaging/Container Fair
Supplies/Transfer Zone
Materials Process Zone
Bioprocess/Biopharma Manufacturing Technology Zone
Laboratory Measurement Analysis Equipment Zone
Label/Labelling Fair
Pharma RFID/Barcode Fair

Energy-saving Solution/Facility Fair
This fair is specialised for various energy solution services, equipments, and machines, as the demand for this area is expanding rapidly in the pharmaceutical and cosmetics industries.

Large companies such as The Tokyo Electronic Power (TEPCO), Takasago Thermal Engineering, and Techno Ryowa exhibited.

PHARMA & COSMETICS LOGISTICS 2009

This expo gathers all logistics solutions specialised for pharmaceutical and cosmetics
industries. Companies gathered products concerning machines and outsourcing services.
Companies such as Mitsuisoko, DHL Supply Chain, Hitachi Transport System, Hitachi
Distribution Software gathered in this area.

Pharma & Cosmetic Packaging/Container Fair

This area especially expanded this year, as in addition to pharmaceutical industy, cosmetic industry industy emerged in. For example, Yoshida Glass and Takemoto Yohki, which is originally from cosmetic industry gathered in this area, in addition to large companies, such as Sogo Printing & Packaging Technopack, Asahi Printing, and Taisei Kako Aptar Pharma Japan .

PHARMA i JAPAN 2009

What is PHARMA i JAPAN?
It is an international trade fair specialized in pharmaceutical ingredients.

Exhibit Profile
Active pharmaceuticdal ingredients
Antibiotics
Chemicals
Formulation development
PHARMA i JAPAN 2009
Fine chemicals |
Synthetic organic chemistry
Tissue culture medias

Growing Demand of PHARMA i JAPAN 2009

Due to the amendment of Pharmaceutical Law that has been enforced this June,

pharmaceutical chemists no longer need to sell drugs, as second-class drug dealers took place. Due to this change, places such as convenience stores, drug stores, and super markets are able to handle products with only second-class drug dealers present. Therefore, the needs of pharmaceutical ingredients are emerging, as more selling points are in existence. Under these circumstances, PHARMA i JAPAN 2009 is actively in application, with visitors in search of suppliers and for serious business meetings held within the exhibition area.

Highlights of Exhibitors and PHARMA i JAPAN

Various international companies came to exhibit this year, such as Roche Diagnostics, Johnson Matthey Japan , Lanxess Saltigo, and so on, expanding widely than the previous edition.

In addition to the exhibition area, PHARMA i JAPAN Academic Forum was newly launched this year. As this area provides new technologies and developments of professors and researchers, it came as an indispensible place for networking and collaboration within scientists and companies.

Conferences/Seminars

One of the other attention getter is the conference held inside the conference hall next to the exhibition. This year, some of the world’s top leaders came to do a speech within the 3 days, with 9,714 attendees gathering to catch up on the latest trends, and the cutting-edge technologies and companies’ strategies. Some of the highlights of seminars are as below.

INT’L BIO FORUM & BIO EXPO JAPAN KEYNOTE SESSION

Therapeutic Antibodies and Vaccines
--Building Novel Pharmaceutical Industry Integrating Chemistry and Biology--

Building Better Biologics:
Potential Approaches to Modifying Activities of Antibodies
Executive Vice President, Research & Development,
MedImmune
Peter Kiener

Abstract: The use of monoclonal antibodies (mAb) to intervene in diseases is now well established. One of the advantages that these macromolecules offer over small molecule drugs is their ability to be modified to better tailor the activity towards the disease and/or host. I will discuss with examples how one may enhance the activity of protein therapeutics by modifying the affinity, effector, function, half life, specificity and more of the biological.

A New Paradigm Shift in Drug Discovery Research
Executive Vice President, Member of The Board,
Chugai Pharmaceutical Co., Ltd.
Tatsumi Yamazaki

Abstract: The success of biopharmaceuticals and antibody drugs and the emergence of molecularly-targeted drugs are paving the way for new drug therapies such as those for cancer. Furthermore, developments in genomics and therapeutics are starting to provide powerful momentum for drug developments in personalized medicine. This presentation will examine new trends in discovery research.

Viruses, Epidemics and Their Control with Emphasis on HIV
Director and Professor,
Institute of Human Virology of the University of Maryland School of Medicine
Robert C. Gallo

Abstract: This presentation will focus on the concepts and technology that led us to the discovery of human retroviruses, the lessons of the early period (1970ies) including some shortsightedness and over-confidence in the field of biotechnology, and a summation of HIV/AIDS current research and approaches to develop a preventive vaccine.

INT’L BIO FORUM & BIO EXPO JAPAN SPECIAL SESSION 7

ES/iPS Cells and its Potential -- Future Applications to Tissue-engineering and Drug Discovery--

First Application of Pluripotent Stem Cells (ES/iPS cells):
Indispensable Tools for Drug Discovery and Safety Test
Director, Institute for Integrated Cell-Material Sciences,
Kyoto University
Norio Nakatsuji

Abstract: Despite restrictions for obtaining human cells for drug discovery and safety tests, with Pluripotent Stem Cells (ES/iPS cells) an unlimited supply of necessary cell species is made possible after proliferation. Genetic modification is also possible for specific purposes such as disease-models. Significant developments are being seen in R&D for drug discovery and practical applications.

Development of HESC-derived Oligodendrocyte Progenitor Cells for the Treatment
of Spinal Cord Injury
Senior Vice President & Chief Scientific Officer,
Geron Corp.
Jane S. Lebkowski

Abstract: HESC-based regenerative cell therapies require ① evidence for reliable production and quality control of product manufacturing, ② rigorous safety testing in preclinical models, and ③ the design of clinical trial protocols that assess the safety and benefit of the therapy in appropriate patient populations. GRNOPC1 is a population of allogenic cells containing oligodendrocyte progenitors derived from characterized, dedicated, human embryonic stem cell banks. GRNOPC1 induces myelination of axons in rats with spinal cord injuries and in Shiverer mice, which lack compact myelin, and also produces numerous neurotrophic factors such as midkine, BDNF, and activin. Extensive preclinical studies were performed to determine the distribution of GRNOPC1 as well as any potential toxicities after injection near the thoracic injury epicenter. Based on this IND application, the FDA has granted clearance for Geron to initiate a human clinical trial to assess the safety of GRNOPC 1 in patients with subacute, complete ASIA A, thoracic injuries whose last fully preserved neurological level is T3 to T10.

INTERPHEX JAPAN KEYNOTE SESSION

Future Prospects of the Japanese Pharmaceutical Industry and Tips for Further Development

Strategies of Astellas and Prospects on Global Pharmaceutical Industry
Representative Director, President & CEO,
Astellas Pharma Inc.
Masafumi Nogimori

Abstract: Every drug manufacturing enterprise in the world is casting about for a variety of business models. Furnishing the agreement of the Pfizer Wyeth purchase, once more the opportunity arises for large industry reorganization on a global level. In what way does the drug manufacturing business maintain a competitive edge? I would also like to base our considerations on the illustration of our company’s global strategy.

Japan Pharma Strategy --How to Face Global Strategy--
Chairman,
Bayer Yakuhin, Ltd.
Norikazu Eiki

Abstract: While the globalisation of the medical supplies industry accelerates, in Japan , what kind of options are there for growth strategy? With regard to research and development, clinical trials, manufactured product strategies and global strategy, etc,I will discuss those scenarios extensively.

INTERPHEX JAPAN SPECIAL SESSION 4

The Global Standard of Pharmaceutical Quality Assurance
How to Facilitate a Quality Assurance System in Japan
Based on the Concept of ICH Q Trio
GMP Expert, GMP Audit Div.,
Office of Compliance and Standards, Pharmaceuticals and Medical Devices Agency,
Takao Kiyohara

Abstract: ICH guidelines for Q8 (Pharmaceutical Development), Q9 (Quality Risk Management) and Q10 (Pharmaceutical Quality System) are being reviewed at Q-IWG to facilitate the implementation. The speech will detail the guidelines, and present the future direction of the efforts to be made in Japan .

Global Pharmaceutical Quality Systems based on ICH-Q trio
--Global Industry Perspective--
CMC Pharmaceutical Consultant
Chris Potter

Abstract: The presentation will discuss establishment of a global pharmaceutical quality system in compliance with ICH Q10. Challenges that arise from operating this global system will be presented including supplying products manufactured applying quality by design, for example if a product has approval in the west for ‘real-time release’.

Global Pharmaceutical Quality Systems and its Example in the West
Quality Operations Leader, Pfizer Global Manufacturing,
Patented Products Business Unit, Pfizer Inc.
John O’Sullivan

Abstract: The presentation will describe the key elements of a global pharmaceutical quality system and outline how the quality system at Pfizer, which covers the key stages of the product lifecycle from development to manufacturing, has been developed and implemented.

PHARMA i JAPAN Special Session 1

Drug Discovery Approaches and Scale-ups for Industrial Applications

Key Points of Scale-up and Troubleshooting in the Production of API
President,
Pharma Research Consulting Office
Mitsunori Hashimoto

Abstract: In the rapidly changing economical condition by the financial crisis over the world, even pharmaceutical companies have been struggling for survival. In such sever time, effective development of new drugs is very important and process chemistry takes a key role as part of this flow. How to avoid troubles and troubleshooting in the process of scale-up and make effective production , it is important business to affect the fate of the companies. These troubleshooting methods should be mentioned.

Chiral Technologies for Globalizing Drug Development
--Daicel’s Challenge--
General Manager, Planning & Development, CPI Company,
Daicel Chemical Industries, Ltd.
Takeshi Matsumoto

Abstract: The Pharmaceutical companies have been accelerating their movement to reduce the term required to commercialize new innovative drugs and to develop more environmental friendly process. Based on the movements, pharmaceutical related companies including service providers has been proposing new technologies and services on a global basis. Today, Daicel’s approach relating to chiral technologies will be introduced.

For full information on the seminar, please visit the below website.
http://www.interphex.jp/ipj/english/conference2009/  
http://www.bio-expo.jp/bio/english/conference2009/  

Next Show 2010

INTERPHEX JAPAN , INT’L BIO FORUM & BIO EXPO JAPAN , and PHARMA i JAPAN have all expanded this year from the previous year, regardless of the severe economic situation. This fact indicates how these life science events are indispensible one for the pharmaceutical industries. Another increase is expected again for the next year.

For 2010, the dates of the 3 exhibitions will be held from June 30 th (Wed) –2 nd (Fri). Mark your calendar now to visit the Asia ’s largest pharmaceutical/bio event!

For Inquires:
INTERPHEX JAPAN Show Management
INT’L BIO FORUM & BIO EXPO JAPAN Show Management
PHARMA i JAPAN Show Management

Reed Exhibitions Japan Ltd.
TEL: +81-3-3349-8509 FAX: +81-3-3349-4922 E-mail:  nomurak@reedexpo.co.jp
WEB:  http://www.interphex.jp/en/     www.bio-expo.jp/en/ 
 http://www.pijapan.jp/en/ 
Attn: Kayo Nomura (Ms.)